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Abstract
Pathogenic variants in the X‐linked gene ZC4H2, which encodes a zinc‐finger
protein, cause an infrequently described syndromic form of arthrogryposis
multiplex congenita (AMC) with central and peripheral nervous system
involvement. We present genetic and detailed phenotypic information on 23
newly identified families and simplex cases that include 19 affected females from
18 families and 14 affected males from nine families. Of note, the 15 females
with deleterious de novo ZC4H2 variants presented with phenotypes ranging
from mild to severe, and their clinical features overlapped with those seen in
affected males. By contrast, of the nine carrier females with inherited ZC4H2
missense variants that were deleterious in affected male relatives, four were
symptomatic. We also compared clinical phenotypes with previously published
cases of both sexes and provide an overview on 48 males and 57 females from
42 families. The spectrum of ZC4H2 defects comprises novel and recurrent
mostly inherited missense variants in affected males, and de novo splicing,
frameshift, nonsense, and partial ZC4H2 deletions in affected females. Patho-
genicity of two newly identified missense variants was further supported by
studies in zebrafish. We propose ZC4H2 as a good candidate for early genetic
testing of males and females with a clinical suspicion of fetal hypo‐/akinesia and/
or (neurogenic) AMC.
K E YWORD S
fetal hypo‐/akinesia, club foot/‐feet, complicated spastic paraplegia/ spasticity, Xq11.2
microdeletion, ZC4H2, ZC4H2‐Associated Rare Disorders (ZARD)
1 | INTRODUCTION
Arthrogryposis multiplex congenita (AMC) has a prevalence of one case
per 3,000–5,000 newborns. It is defined as multiple joint contractures
that involve at least two different body areas before birth. AMC is a
descriptive term and present in over 400 specific conditions (Hall, 1984,
2014). One known causal factor is decreased fetal movement in utero
(fetal hypo‐/akinesia; Hall, 2009). AMC can result from a single gene
defect or a chromosomal abnormality and can be part of various
syndromes. In these cases, autosomal dominant, autosomal recessive, and
X‐linked inheritance are possible (Hall, 2014). There are currently over
800 genes connected with either arthrogryposis or other types of early
contractures with over 150 forms due to deleterious defects of X‐linked
genes (Hunter et al., 2015).
One form of X‐linked arthrogryposis was first described in 1985 in six
men from three generations of one family and referred to as Wieacker‐
Wolff syndrome (WRWF; MIM# 314580; Wieacker, Wolff, Wienker, &
Sauer, 1985). All six affected had congenital contractures of the feet,
slowly progressive predominantly distal muscle atrophy, visual dyspraxia,
facial weakness, and intellectual disability (ID). In 2013, this family was
reported to carry a pathogenic missense variant of the X‐linked gene
ZC4H2 (MIM# 300897) along with three additional unrelated families
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who carried ZC4H2missense variants in males and females, an unrelated
male with a de novo chromosomal inversion that truncated ZC4H2, and
two unrelated females harboring heterozygous de novo ZC4H2 deletions
(Hirata et al., 2013). In zebrafish, zc4h2 knockdown caused abnormal
swimming and impaired alpha‐motor neuron development, which could
not be rescued by mutant proteins containing the pathogenic substitu-
tions (Hirata et al., 2013).
In 2015, May et al. identified ZC4H2 variants in four additional
families, including a large family with syndromic X‐linked ID (XLID;
MRXS4), previously described as having Miles‐Carpenter syndrome
(MCS; Miles & Carpenter, 1991) and characterized by XLID,
exotropia, distal muscle wasting, microcephaly, congenital contrac-
tures, and low digital arches (May et al., 2015). Most recently, three
simplex females with heterozygous de novo deleterious ZC4H2 were
reported, including an early truncating nonsense variant and two
microdeletions (Godfrey, Dowlatshahi, Martin, & Rothkopf, 2018;
Okubo et al., 2018; Zanzottera et al., 2017). As a result of these
findings, these various allelic syndromes are now referred to as
ZC4H2‐associated rare disorders (ZARD).
We here report 23 additional ZARD families and simplex
cases with inherited or de novo pathogenic ZC4H2 variants plus
three cases with publicly available information in DECIPHER
(https://decipher.sanger.ac.uk/). We compared the genetic and
clinical results with previously published families, thereby
extending the molecular and clinical spectrum of ZARD through-
out life, and discuss the broad clinical spectrum and its clinical
variability in both males and females. Furthermore, we report a
late adult‐onset mild form of slowly progressive spastic para-
plegia in ZC4H2 carrier females of one previously published
family (Hennekam, Barth, Van Lookeren Campagne, De Visser, &
Dingemans, 1991; Hirata et al., 2013). We emphasize that the
ZARD phenotype in females with a pathogenic de novo ZC4H2
variant can be highly variable.
2 | MATERIALS AND METHODS
2.1 | Editorial policies and ethical considerations
The study was carried out in accordance with the Declaration of Helsinki
and the protocol approved by the local ethical committees for clinical
genetic investigations. Written informed consent was obtained for
molecular genetic analysis, publication of clinical, radiological data, and
photographs from all participants or their legal guardians.
2.2 | Genetic studies
DNAs were extracted from peripheral blood, skin fibroblasts, buccal
cells, or umbilical cord using standard procedures.
Families 1, 14, 16, and 18 (DECIPHER Patient IDs: 263304,
263305, 260529, 276496, and 296515) were recruited to the
Deciphering Developmental Disorders (DDD) study. DNA samples
were analyzed by the Wellcome Sanger Institute using array‐CGH
and whole exome sequencing (WES; Wright et al., 2015). For
families 2, 8, 13, 15, 19, and 24 trio WES was performed as
described in more detail in Supporting Information Materials and
Methods, and for families 3 and 5 essentially as reported
previously (Neveling et al., 2013). For families 4 and 6 all ZC4H2
coding exons were amplified by polymerase chain reaction (PCR)
and Sanger sequenced with gene‐specific primer pairs previously
published (Hirata et al., 2013). Also for family 6, all TYR and OCA2
coding exons were amplified by PCR and Sanger sequenced. For
family 7, see, Hennekam et al. (1991) and Hirata et al. (2013). For
family 9 WES was performed for the index proband (Figure 1, V:1),
his unaffected parents (III:1 and III:2) and two of his affected male
relatives (III:5 and IV:2). For family 17 WES was performed for the
index proband (Figure 1, II:1) in a research context. For families 3
(umbilical DNA of II:3), 10, 11, 12, 20, and 23 array‐CGH was
carried out, and for family 12 the breakpoints of the chromosomal
deletion were fine‐mapped by serial PCR and bidirectional Sanger
sequencing (for further details see Supporting Information and
Figure S1). For family 21, trio whole genome sequencing (WGS)
was performed on peripheral blood DNA from the proband and
both parents through the 100,000 Genomes Project (The 100,000
Genomes Project Protocol v3, Genomics England. doi:10.6084/
m9.figshare.4530893.v3. 2017). For family 22, trio WGS was
performed on saliva DNA at Baylor Genome Center as part of the
NIH Gabriella Miller Kids First Research Program. For this family,
the GeneMatcher and matchbox nodes of the Matchmaker
exchange database were used to obtain collaborations using the
search term ZC4H2 (Arachchi et al., 2018; Philippakis et al., 2015;
Sobreira et al., 2017). For family 24 trio WES was performed at
Fulgent Genetics, US.
The ZC4H2 variants identified by WES and WGS were subse-
quently confirmed in the patients using Sanger sequencing. Segrega-
tion analysis of the variants was performed using standard Sanger
sequencing with gene‐specific primers and for family 9 using
restriction digestion of the specific PCR product (see Supporting
Information for more details).
The novel ZC4H2 variants identified through this study have been
submitted to the LOVD database (https://databases.lovd.nl/shared/
genes/ZC4H2).
2.3 | X‐inactivation studies
For X‐inactivation studies, DNA extracted from blood lymphocytes or
skin fibroblasts was analyzed for the methylation sensitive site of
FMR1 exon 1 (Carrel & Willard, 1996), the CAG‐repeat of the
Androgen Receptor (AR) gene (Allen, Zoghbi, Moseley, Rosenblatt, &
Belmont, 1992), or of ZMYM3.
2.4 | In silico analysis
The pathogenicity of missense variants was assessed using in
silico tools including Combined Annotation Dependent Depletion
(CADD, http://cadd.gs.washington.edu/) score (Kircher et al.,
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F IGURE 1 Pedigrees of the families with pathogenic ZC4H2 variants discovered by candidate gene approach, whole exome/genome
sequencing and array‐CGH. Families 1, 4–6, 8, 9, 15, 18, 19, and 24 with likely pathogenic ZC4H2 missense variants, families 2, 3, 13, 14, 16, 17,
21, and 22 with splicing, frameshift, and stop codon variants and families 10–12, 20, and 23 with a microdeletion removing the 5′ part of ZC4H2,
Fam, family; *, variant present; wt, wild‐type. For family 7 see Figure S2
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2014) and Provean (http://provean.jcvi.org/index.php; Choi &
Chan, 2015).
2.5 | Extraction of variants and clinical phenotypes
from the literature and the DECIPHER database
We established a list of all published ZC4H2 variants reported in the
literature as of January 2019 and three cases from DECIPHER, and
included available clinical information in our analysis.
2.6 | Knockdown and rescue experiments in
zebrafish
Zebrafish were bred and maintained according to approved guidelines
prescribed by the Committee on Use and Care of Animals at Aoyama
Gakuin University (Japan). Zebrafish zc4h2 (GenBank NM_199642)
cloned into pCR4‐TOPO vector (Invitrogen) was used for cRNA synthesis
as previously described (Hirata et al., 2013). Antisense morpholino
oligonucleotides (MO) designed against the exon 2‐intron 2 splice donor
site (MO2) of zebrafish zc4h2 were used for knocking down zc4h2.
Zebrafish embryos were injected with 5 ng of MOs at 1–2 cell stages and
studied as published before (Hirata et al., 2013). For rescue experiments,
the missense variants were introduced into the wild‐type mouse Zc4h2
(RefSeq NM_001003916.2) pCS2+ expression construct by site‐directed
mutagenesis (primer sequences are provided in Table S1). Capped RNA
was synthesized using mMESSAGE mMACHINE SP6 kit (Life Technol-
ogies) according to the manufacturer's protocol. Capped RNA (100pg)
was coinjected with MO2 (4 ng) into zebrafish embryos at 1–2 cell stages.
At 2 days postfertilization, normal zebrafish embryos swim away rapidly
(> 2 cm/s) upon tactile stimulation. The number of embryos that exhibited
slow swimming (< 2 cm/s) following touch was counted.
2.7 | ZC4H2 reference sequence
All ZC4H2 variants reported are based on GRCh37/hg19 and
transcript isoform 1 (RefSeq NM_018684.3) with nucleotide (cDNA)
numbering using +1 as the A of the ATG translation initiation codon
in the reference sequence, with the initiation codon as codon 1.
3 | RESULTS
3.1 | Clinical features in the new patient cohort
and in previously published families
We report on 23 novel families and simplex cases with likely
deleterious ZC4H2 variants and on one previously published family,
family 7 of this study (Hennekam et al., 1991; Hirata et al., 2013). The
pedigrees of the novel families are shown in Figure 1 (Fam1–6 and
Fam8–24) and of family 7 in Figure S2. Detailed clinical descriptions
are presented in Supporting Information Results. In the clinical
evaluation, we also included publicly accessible information of three
females reported to DECIPHER and all families and simplex cases
published to date (Godfrey et al., 2018; Hirata et al., 2013; Kondo
et al., 2018; May et al., 2015; Okubo et al., 2018; Zanzottera et al.,
2017). A compilation of the main (≥ 30%) clinical features of affected
males and females from these 42 families is given in Table 1 and of
the additional less common clinical features (< 30%) in Table S2.
Percentages are related to the total number of probands who were
clinically evaluated for a given feature (positive informative). In total,
informative clinical data were collected for 87 out of 105 (83%)
probands, including 44 out of 48 (92%) males and 43 out of 57 (75%)
females using the Human Phenotype Ontology (https://hpo.jax.org/
app/) scoring list. Their ages ranged from 23 weeks of gestation
to > 70 years at the time of clinical genetic investigation. Families
were recruited worldwide and were of Caucasian and Asian ethnicity.
Prenatal presentation of five fetuses with ZARD (two males and
three females), included club foot/feet, rocker bottom feet, fetal
hypo/akinesia (mostly at the end of the second or third trimester of
pregnancy, > 18–26 weeks of gestation), contractures, AMC, nuchal
and/or frontal head edema and (nearly) normal growth parameters
(See Videos S1–3 and Figure S3). One affected male fetus presented
with hypogenitalism (cryptorchidism and micropenis).
At birth and neonatal age, the clinical genetic diagnosis in males
varied from descriptive clinical features, for example, AMC with or
without additional clinical features including: Psychomotor develop-
mental delay, short stature, brain atrophy, microcephaly, tetraplegia,
congenital general hypotonia, facial weakness‐palsy, muscle weak-
ness, and complex spasticity, (flexion) contractures of large and/or
small joints, congenital hip dislocation – subluxation, rocker bottom
feet, club feet, camptodactyly, and ptosis, to (un)recognizable
syndromes, such as cerebral palsy, MCS, WRWF with or without
cleft palate, feeding difficulties, laryngomalacia, hyperinsulinemic
hypoglycemia, mixed obstructive, and central sleep apnea.
The clinical genetic features in 33 newly identified and published
carrier females (from childhood till late adulthood) with a maternally
inherited ZC4H2 variant varied from normal phenotype (n = 13) to
mild (mainly hand‐finger) flexion contractures, borderline to mild ID
(n = 20) with facial dysmorphism such as ptosis, strabismus, and long
(flat) philtrum. Also, distal muscle weakness, urine (stress) incon-
tinence, anosmia, and walking difficulties which were slowly
progressive in a few (n = 3) females in late adulthood were reported.
In marked contrast, the 25 females with a de novo pathogenic
variant (from neonatal age till adulthood) of ZC4H2 including Xq11.2
microdeletions showed high variation in clinical presentation and
ranged from mildly to severely affected (Table 1; Table S2).
Overall, common clinical features in child‐ and adulthood in both
males and females (30% or more positive informative in probands)
included postnatal growth retardation, generalized hypotonia, motor
delay, inability to walk, spasticity, hyperreflexia, urinary incontinence,
dysarthria‐deficit in expressive language, poor or absent speech, ID,
drooling, dysphagia, chewing difficulties including oral motor dys-
function, feeding difficulties, facial weakness‐palsy, high forehead,
high anterior hairline, ocular motor apraxia, strabismus, anteverted
nares, microretrognathia, AMC, limited shoulder movement, elbow,
wrist contractures, metacarpophalangeal joint contractures, campto-
dactyly, radial deviation of any finger, knee flexion contractures,
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equinovarus deformity‐club feet, Achilles tendon contracture, distal
limb muscle atrophy, or weakness, and micropenis or cryptorchidism
in males (Table 1; Table S2, Figures S4 and S5).
Less commonly reported clinical features, which were present in
<30% of the probands included short stature, microcephaly (more
prominent in males (16/26) than in females (4/30)), round face,
low‐set (posteriorly rotated) ears, upslanting palpebral fissures,
almond‐shaped eyes, ptosis, deeply set eyes, pupillary dysfunction,
nystagmus, short nose, short philtrum, broad alveolar ridges, high‐
arched palate, and (submucous) cleft palate (Figures S3 and S4).
Furthermore, U‐shaped upper lip vermillion/carpshaped mouth and
downturned corners of the mouth were reported. A short neck (with
limited rotation) was more frequently reported for females with a de
novo variant (12/14) than for affected males with an inherited or de
novo variant (12/37; Table 1; Table S2, Figure S5). Of note, neonatal
respiratory distress, recurrent aspiration pneumonia, and (obstruc-
tive sleep) apnea can be a particular concern with apnea more
frequently reported in males (11/16) than in affected females with a
de novo variant (3/11). In addition reported clinical features included
narrow chest, narrow shoulders‐thorax (more frequently reported in
females with a de novo variant (11/15) than in affected males
(18/36); Figure S5), umbilical hernia (Figure S3A, 6.III:1), cervical and/
or thoracic kyphosis, scoliosis, narrow pelvis, congenital hip
contracture, hip dislocation/subluxation, short limbs, proximally
placed thumb, ulnar deviation of any finger, overlapping – proximally
placed toe(s), edema of the dorsum of hands and feet (Figure S5),
generalized hypotonia, absent speech, epileptic seizures, abnormal
cortical gyration, delayed CNS myelination, global brain atrophy, and
ventriculomegaly (Figure S6). So far, impaired smell was only
reported in carrier females in late adulthood. Upslanting palpebral
fissures (Figure S4), arrhythmia, sick sinus syndrome, hypoglycemia,
and aggressive behavior were so far only reported in males (Table 1
and Table S2).
Besides the ZARD typical features such as AMC, hypo‐/akinesia,
club foot/feet and facial dysmorphy, associated sporadic clinical
features which can be a clue to clinical diagnosis in probands with
ZARD include pupillary dysfunction, optic disk cupping, short
neck with limited rotation with narrow chest – thorax – shoulders
with limited shoulder movements, malposition of the stomach,
diaphragmatic eventration, focal autonomic seizures, electrical status
epilepticus during slow sleep (ESES) seizure pattern on electro-
encephalogram (EEG), pancreatic hypoplasia (and postprandial
hypoglycemia), and congenital achalasia (Table S2).
Central and peripheral neurological findings in affected individuals
included: ID, poor or absent speech, dysarthria, deficit in expressive
language, dysphagia, drooling, and chewing difficulties including oral
motor dysfunction, motor delay, inability to walk, spasticity, hyperreflexia,
areflexia, and dystonia. Various types of seizures, generalized hypotonia,
impaired smell (3/13, adult carrier females), and urinary (stress)
incontinence (16/28) were also mentioned.
MRI brain and spine images showed variable and global brain
atrophy (11/31; examples are given in Figure S6), delayed CNS
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(4/27), corpus callosum abnormality (7/26), abnormal cortical
gyration (5/24), ventriculomegaly (8/20), polymicrogyria, anterior to
posterior gradient (1/8 males), tethered cord (3/19), and hydromyelia
(2/10 males). Abnormal peripheral nerve conduction was present in
one affected (1/7 males). Behavioral phenotypes included emotional
lability (5/14) and aggressive behavior (3/5 males; Table S2).
Cardiovascular associated clinical features, for example, arrhyth-
mia (5/13), bradycardia (5/8), (congenital) sick sinus syndrome (5/13),
and right ventricular hypertrophy (4/12) were so far reported in
affected males only (Table S2).
3.2 | ZC4H2 genetic characteristics in the new
cohort and global mutational spectrum
Most of the novel families were investigated by WES, WGS and/or
array‐CGH. For two affected index males (family 4, II:2 and family 6,
III:1) it was assumed that the phenotype could be caused by a
pathogenic ZC4H2 variant and therefore all coding exons were
screened by Sanger sequencing.
A total of eight males from six families (families 1, 3, 4, 5, 9, and 19)
inherited the variant from a healthy carrier mother, while three males
from three families (families 5, 6, and 9) inherited the variant from a
mildly affected mother (Figure 1). For one affected male (family 9, II:5)
the phenotype of his mother is unknown. In the moderately affected male
from family 18 (Figure 1, II:1 and Figures S4 and S5) and the severely
affected male from family 24 (Figure 1, II:1) the missense variant
occurred de novo.
In 15 females the variant occurred de novo (Figure 1), including
individual II:1 from family 6 who presented with contractures of her
metacarpophalangeal finger joints and is otherwise healthy. By
contrast, the female fetus of family 3 (Figure 1, II:3) inherited the
pathogenic variant from her healthy mother who is a mosaic and
carries the variant in about 10% of her cells (Figure S7) and the two
mildly affected females from family 9 (Figure 1, II:3 and II:6) carry a
maternally inherited missense variant.
A total of 23 variants were identified (Figure 2a,b,c). Thirteen of
the 23 were de novo loss‐of‐function variants (nonsense, splice‐site,
frameshift, and CNVs) present in affected females and 10 were
missense variants identified in affected males which, except for the
two de novo variants in affected males (families 18 and 24), were
inherited from their mildly affected or asymptomatic carrier mothers.
Twenty of the 23 variants were novel including single nucleotide
variants (SNVs) and five de novo microdeletions in females. The
microdeletions removed the first exon of ZC4H2 but did not affect
any adjacent genes. Two missense variants were defined as
recurrent. Families 4 and 24 of this study carry a previously reported
p.(Arg198Gln) change in an unrelated family (Hirata et al., 2013).
Family 18 of this study has a de novo p.(Arg213Trp) variant
previously reported in three unrelated families (Hirata et al., 2013;
May et al., 2015). Also, in two families in this study (families 5 and 6)
the same amino acid (Ala200) was altered. Finally, the proline residue
201 mutated to serine in a published family (Hirata et al., 2013) was
mutated to histidine in family 19 of this study.
None of the variants identified in this study were reported in publicly
available population databases, including the 1000 Genomes Project
database and Genome Aggregation Database (gnomAD, http://gnomad.-
broadinstitute.org/). Also, there were no deletions reported in the
database of genomic variants (DGV, http://dgv.tcag.ca/dgv/app/home?
ref=GRCh37/hg19) overlapping ZC4H2 exons, demonstrating that the
variants identified in the patients are likely not common polymorphisms
and supporting our suggestion that they are deleterious to protein
function. All missense variants altered highly conserved amino acids (fully
conserved from human to zebrafish; Figure 2d and Figure S8). Also, in
silico predictions using CADD revealed high scores (> 22) and using
Provean all variants were predicted as deleterious, except for the
p.(Lys217Arg) change, which perfectly cosegregated with the phenotype
in a large family (Fam9). At the gene level, ZC4H2 is highly constrained
with a pLI score of 0.91 and zero known LOF mutations in gnomAD (Lek
et al., 2016).
Combined with our results of this study, there are currently 31
unique ZC4H2 variants known in affected males and females, including
one de novo X‐inversion interrupting ZC4H2 in a male plus 10 de novo
Xq11.2 microdeletions in females (Figure 2a). An overview of all variants
is provided in Table S3. Thus far, SNVs leading to missense changes
cluster in the last exon of ZC4H2, which encodes the zinc‐finger domain
and the most C‐terminal part of the protein.
The X‐inactivation pattern in blood or skin fibroblasts in affected
females varied from random to skewed and was not useful to predict
the phenotype (Figure 1 and Supporting Information Results), for
example, one severely affected female fetus showed an Xi ratio of
61:39 in skin fibroblasts (Figure 1, Fam3, II:3). Other mild to severely
affected females showed Xi ratios varying between 100:0 and 80:20
(Figure 1) in blood lymphocytes. Previous asymptomatic carrier
females reported in the literature showed also a ratio of > 95:5 (e.g.,
Hirata et al., 2013).
3.3 | Zebrafish studies
We investigated the potential effects of the p.(Ala200Val) and
p.(His70Gln) missense variants which we identified early on in
zebrafish morphants similar to our previous studies (Hirata et al.,
2013). Following knockdown of zc4h2, zebrafish morphants showed
impaired swimming capability at 2 days postfertilization (27/34, 79%
of morphants) due to compromised swimming contraction. This
defect could be rescued with wild‐type Zc4h2 (7/29, 24% of
morphants), but not with constructs carrying the p.(Ala200Val) (27/
35, 77% of morphants) or p.(His70Gln) (29/41, 71% of morphants)
variants and thus the results strongly supported pathogenicity of the
altered amino acids.
4 | DISCUSSION
This study reports on the genetic and clinical findings of 23 novel
families and simplex cases with deleterious inherited or de novo
ZC4H2 variants identified in males and females, including de novo
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F IGURE 2 Overview of genetic results in ZARD affected males and females. An overview of newly identified likely pathogenic variants of ZC4H2
described here and previously reported in the literature. (a) Schematic view of the X chromosome with the location of ZC4H2 and the five known RNA
isoforms. Horizontal bars indicate the de novo complete ZC4H2 deletions in affected females published previously (Hirata et al., 2013; Okubo et al.,
2018; Zanzottera et al., 2017), DECIPHER case 323746 and the newly identified de novo ZC4H2 microdeletions removing part of ZC4H2 identified in
this study (families 10–12, 20, and 23). All deletions removed ZC4H2 exon 1 but no other known gene. (b) The structure of human ZC4H2 (Isoform 1;
NM_018684.3) with nontranslated sequences gray‐striped, exons encoding the coiled‐coil domain in gray, and exons encoding the zinc‐finger domain in
white. Newly identified pathogenic ZC4H2 variants identified in this study are depicted above the gene with de novo variants in affected females
underlined. Likely pathogenic variants from the literature are depicted below the gene and protein. (c) Schematic representation of ZC4H2 protein
isoform 1 (NP_061154.1) with its functional domains (CC domain: Coiled coil domain; ZNF: zinc‐finger domain). ZC4H2 variants newly identified in this
study are depicted above the protein with de novo variants in females underlined and variants from the literature are depicted below the protein. (d)
Multiple sequence alignment of ZC4H2 protein sequences in five species showing 100% conservation of the newly identified mutated amino acids
(boxed). Amino acids of the ZC4H2 zinc‐finger domain in the C‐terminal part of the protein are underlined
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partial ZC4H2 microdeletions present in affected females only, and a
review of the ZARD literature. Moreover, we have investigated
pathogenicity of two single amino acid substitutions in zebrafish as
described before (Hirata et al., 2013).
Inherited and de novo variants are present in all coding exons and
there is no hotspot in the gene. On the protein level, most of the
missense changes lie within the C‐terminal part of ZC4H2 including
the zinc‐finger domain. All mutated amino acids of ZC4H2 are highly
conserved and predicted to be functionally relevant. The two
missense variants tested in zebrafish resulted in impaired swimming
of the mutants, supporting functional importance of the mutated
amino acids. Two of the de novo pathogenic missense variants
identified in females (families 8 and 15, p.(Cys206Phe) and
p.(Cys203Ser) respectively) altered one of the four cysteine residues
of the Cys4His2 type zinc‐finger. The function of this zinc finger is
currently unknown.
Most ZC4H2 pathogenic variants identified in affected males are
missense changes and, except for two de novo missense variants
identified in affected males (families 18 and 24), were inherited from
mostly asymptomatic mothers (X‐recessive). This is well in line with
previous findings. To the best of our knowledge, with only two exceptions
there are no pathogenic variants reported in affected males predicted to
lead to a truncated or completely absent ZC4H2 protein. The two
exceptions are the de novo X‐chromosome inversion which disrupted
ZC4H2 at one of the breakpoints in a severely affected boy (Hirata et al.,
2013) and the affected boy from family 3 who we assume, based on
clinical presentation, carried the maternally inherited p.(Glu92Vfs*7)
variant but did not undergo genetic testing. He was born after Caesarean
section because of fetal distress at 40 weeks pregnancy with multiple
congenital malformations and died 10hr after birth because of
respiratory distress. He had short limbs, AMC and a cleft palate. Affected
males can have syndromic variable XLID (mild‐moderate ID) with (mild)
hypotonia, spasticity (as seen in SPG16 [Steinmuller et al., 1997]), mild
facial dysmorphism, for example, high forehead with high frontal hairline,
ocular dyspraxia, relative short stature, and (relative) microcephaly. The
differential diagnosis is still challenging and earlier reported XLID families
could benefit from WES including ZC4H2 analysis (Table S4).
In contrast to the mostly inherited missense variants in affected
males, the spectrum of de novo pathogenic ZC4H2 variants identified
in affected females includes missense, early stop, frameshift and
splicing variants, as well as Xq11.2 microdeletions which removed
ZC4H2 completely or exon 1 of all transcript isoforms. Thus, from the
current data it seems that pathogenic variants predicted to lead to a
complete loss of ZC4H2 protein function are very rare in males, while
they usually occur de novo in females. Of note, none of the
pathogenic variants identified in males were found de novo in female
simplex cases. The de novo variants in the affected females are
predicted to be loss‐of function alleles, suggesting ZC4H2 insuffi-
ciency as the most likely pathological mechanism leading to an X‐
linked dominant phenotype.
Our detailed clinical characterization (Table 1 and Table S2)
confirms and extends clinical findings reported for the few published
families and simplex cases caused by deleterious ZC4H2 SNVs in
males and de novo ZC4H2 microdeletions in females. Furthermore,
we report the first mosaic frameshift variant of ZC4H2 in a family
with AMC and fetal hypo‐/akinesia. Combined, the results indicate
that, in males, inherited forms of ZARD are associated with complete
penetrance but variable expressivity, ranging from nonspecific XLID
to XL‐AMC with variable mostly moderate to severe forms of ID,
fetal hypo‐/akinesia, postnatal growth retardation, spasticity, tetra-
plegia, (relative) microcephaly, and hypogenitalism. By contrast, in
females, the inherited forms of ZARD are associated with incomplete
penetrance and variable expressivity, ranging from unaffected
carriers to XL‐AMC with variable cognition, postnatal growth
retardation, poor or absent speech, spasticity, inability to walk, distal
muscle wasting/atrophy, short neck with limited rotation, narrow
chest, and limited shoulder movements. Moreover, clinical follow‐up
of family 7 for more than 25 years (Hennekam et al., 1991) indicated
very mild progressive muscle weakness in two former asymptomatic
carrier females and marked progression including loss of the ability
to walk and distal muscle wasting in one carrier female (Figure S2,
III:5, III:7, and III:14). She also had episodic periods of pain of
unknown origin. All three females had inability to smell and urine
stress incontinence. As differential diagnoses a late‐onset mild
progressive syndromic form of spastic paraplegia (SPG), multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS), or Charcot‐Marie‐
Tooth (CMT) were clinically (re)considered. While we cannot exclude
comorbidity with other X‐linked forms of SPG (e.g., PLP1, SLC16A2,
and TAF1), ALS (SMAX1), and CMT (GJB1) which could not be tested
genetically, the females are all carriers of a ZC4H2 pathogenic variant
causing ZARD in their male offspring. This makes it more likely that
their late‐onset phenotype belongs to ZARD's clinical variability. In
contrast to this late‐onset neurodegenerative adult phenotype
reported so far in one family, there is no early‐onset progressive
neurodegenerative phenotype known in affected children.
Compared with males, females with a pathogenic de novo variant of
ZC4H2 presented with a more variable phenotype. Cognition ranged
from normal (families 3, 6, and 23) to mild learning difficulties (families
8, 21, and 22), as reported for affected who carry missense, frameshift
or splicing variants, and a partial gene deletion, respectively, to
moderate or severe ID (families 10–17). Furthermore, clinical char-
acteristics of the de novo Xq11.2 microdeletions present in females
showed that these deletions are associated with a recognizable
phenotype and that the overall clinical outcome varies between mildly
and severely affected and thus cannot be predicted. Speech delay and
poor speech are a remarkable clinical feature in the affected, so speech
therapy should be started as early as possible to optimize communica-
tion leading to improved quality of life. Also, a large Xq11.2 deletion
which, in addition to ZC4H2, removed ARHGEF9, WTX, and MTMR8 was
reported in a female with severe ID and normal X‐inactivation (Holman
et al., 2013). The major clinical phenotype was caused by the WTX
deletion leading to osteopathia striata with cranial sclerosis and it was
suggested that deletion of ZC4H2 contributed to her severe ID. Given
the results obtained through this study it is possible that in addition to
ID other clinical features reported for this female, such as clenched
hands with immobile joints, early‐onset complex partial seizures
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(controlled on levetiracetam), dysphagia, and lower extremity spasticity
could be caused by ZARD.
Two of the pathogenic ZC4H2 missense variants identified in this
study are recurrent. First, the maternally inherited amino acid change
p.(Arg198Gln) identified in the affected males of one family (family 4)
and de novo in the affected male of an unrelated family (family 24)
has previously been reported in a large German family (Hirata et al.,
2013) and there are phenotypic overlaps with affected males being
severely affected. Secondly, the de novo p.(Arg213Trp) substitution
identified in a moderately affected male (family 18) has previously
been reported in three large families (Hirata et al., 2013; May et al.,
2015). The clinical phenotype is variable within and between families,
but all affected males (Family K8615, May et al., 2015, families 4 and
5, Hirata et al., 2013) presented with moderate to severe ID with
absent or poor speech. Mild facial dysmorphism was evident in one
family only (family 5, Hirata et al., 2013). Other common shared
clinical features included motor delay, inability to walk, hyperreflexia,
spasticity, and seizures. Skeletal findings, for example, AMC were
reported in a few affected males (2/2 males of family 4 and 1/2 males
of family 5, Hirata et al., 2013). All female carriers, except one, of the
three families had borderline or mild ID (family K8615, May et al.,
2015, families 4 and 5 Hirata et al., 2013).
Overall, despite the growing number of families and simplex
cases with deleterious ZC4H2 variants, there is currently no evidence
for a clear genotype‐phenotype correlation. Also, as discussed above,
clinical presentations of affected individuals who carry the same
pathogenic variant leading to ZARD can vary within families and
between families. Nevertheless, there are some gender‐specific
clinical features, for example, heart rhythm disturbances and
hypogenitalism in males.
The striking phenotypic differences between females with
inherited X‐linked recessive ZC4H2 missense variants versus de
novo X‐linked dominant deleterious ZC4H2 nonsense, frameshifting
or Xq11.2 microdeletions is similar to that seen for a few other X‐
linked genes, such as ARX (Bienvenu et al., 2002; Mattiske et al.,
2017; Stromme et al., 2002), HDAC8 (Kaiser et al., 2014), PHF6
(Lower et al., 2002; Zweier et al., 2013), IQSEC2 (Ewans et al., 2017;
O'Rawe et al., 2015; Shoubridge et al., 2010; Zerem et al., 2016), and
CLCN4 (Hu et al., 2016; Palmer et al., 2018). Also gender‐specific
pathogenicity differences of inherited variants in males and de novo
variants in females have been reported for other XLID genes, for
example, DDX3X (Dikow et al., 2017; Snijders Blok et al., 2015),
KIAA2022 (Lorenzo et al., 2018; Van Maldergem et al., 2013), MTM1
(Schara, Kress, Tucke, & Mortier, 2003), and CASK (Moog et al.,
2011).
ZC4H2 is known as a gene which is subject to X‐inactivation.
Current results suggest that, in heterozygous carrier females, X‐
inactivation status in blood and skin fibroblasts does not predict the
clinical outcome. This is very much in line with results obtained for
other X‐linked disease genes and also with recent findings suggesting
that skewed X‐inactivation is common in the general female
population (Shvetsova et al., 2018). Still, the variable clinical
manifestations of heterozygous carrier females with a de novo
variant ranging from very mildly to severely affected may be partially
explained by the X‐inactivation status within specific affected cells
and tissues. However, other genetic, environmental, or stochastic
factors may also be involved and could have an impact on phenotypic
variability and severity of ZARD.
Similar to patients with other types of AMC who develop joint
contractures during pregnancy, abnormal fetal movement due to
ZARD can be identified using real time ultrasound prenatally, as we
report here for affected fetuses from several families (for family 3
see Videos S1–3). An early diagnosis of AMC prenatally would allow
parents and clinicians early decision making, for example, the
possibility of in utero therapy (increasing movement in utero), or
early delivery at a time when lungs are mature but the contractures
may not yet be so severe (Hall, Agranovich, Ponten, & van Bosse,
2015). However, AMC and fetal hypo‐/akinesia can occur late in
pregnancy, after routine prenatal ultrasound sonography has taken
place between 18 and 22 weeks of gestation, thus the diagnosis of
AMC and/or fetal hypo‐/akinesia can be easily missed. Moreover,
reduced fetal hand, finger and feet movements are not examined
routinely by ultrasound and occasionally club foot/feet is/are the
only clinical feature which fetuses with a pathogenic ZC4H2 variant
presented prenatally or neonatally.
In conclusion, ZC4H2 is one of the more commonly mutated
XL‐AMC and XLID genes. Up to now de novo pathogenic variants of
ZC4H2 have been more frequently seen in affected females than in
males with ZARD and displayed a broad clinical spectrum ranging
from mildly to severely affected patients with neurogenic AMC with
or without CNS and PNS involvement (see Supporting Information).
Our findings suggest including ZC4H2 analysis retrospectively in
AMC male and female cohorts and prospectively in prenatal and/or
neonatal genetic diagnostic tests in male and female fetuses
presenting with fetal hypo‐/akinesia and/or AMC, for example, (only)
club foot/feet with or without hypogenitalism in males. Long‐term
prospective clinical studies assessing the development of the ZARD
phenotypes and investigations determining the molecular and
cellular mechanisms underlying the disorders are required.
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